Abbott has secured the US Food and Drug Administration (FDA) approval for its next-generation CardioMEMS HERO device, which ...

Abbott Laboratories recently received FDA approval for its redesigned CardioMEMS Hero remote heart failure monitoring system, featuring a smaller, lighter reader aimed at improving patient convenience ...

CardioMEMS ran into a regulatory roadblock last week, when an FDA advisory panel recommended that the agency not approve the company's Champion HF Monitoring System. The device is said to be the first ...

Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (DXR) (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the ...

The CardioMEMS HF System is proven to significantly reduce heart failure hospitalizations and improve quality of life in NYHA class III HF patients St. Jude Medical now intends to exercise its ...

The Food and Drug Administration awarded approval to CardioMEMS Hero, a new version of the device that patients use to take daily pulmonary artery pressure readings. Abbott has made Hero smaller and ...

Oak Ridge, TN, July 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (DXR) (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a new research letter in the Journal ...

ATLANTA, Aug. 26 -- CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today ...

WASHINGTON (Reuters) - A Food and Drug Administration review of CardioMEMS' device for treating heart failure found it has met its main safety and effectiveness goals, based on trial results. But the ...

December 8, 2011 (Gaithersburg, Maryland) — An FDA advisory panel collectively decided a tiny pulmonary-artery (PA) pressure monitor for patients with heart failure (HF) isn't ready for prime time.